NEOVASC INC. NAMED A 2011 TOP 50 COMPANY BY TSX VENTURE EXCHANGE

--Selected for 2011 TSX Venture 50 Award in Technology & Life Sciences--

TSX Venture Exchange: NVC

VANCOUVER, Feb. 16 /CNW/ - Neovasc Inc. (TSXV: NVC), today announced that it has been named to the 2011 TSX Venture 50, a ranking of 50 strong performing companies identified from the more than 2,000 firms listed on the TSX Venture Exchange. Neovasc was selected as one of 10 recipients in the Technology & Life Sciences sector.

"The TSX Venture Exchange includes some of the most dynamic young companies in Canada and we are proud to have achieved the distinction of being among the 50 best performing listed companies," said Neovasc CEO Alexei Marko. "We are optimistic that our progress in 2010 will serve as a foundation for continued growth this year, as we advance our Reducer™ product for refractory angina towards commercialization and continue to expand our PeriPatch™ implantable tissue business for specialized cardiac, vascular and surgical applications."

The TSX Venture 50® are the top 10 companies listed on the TSX Venture Exchange, in each of five major industry sectors - mining, oil & gas, technology & life sciences, diversified industries and clean technology - based on a ranking formula with equal weighting given to return on investment, market cap growth, trading volume and analyst coverage. All data was as of December 31, 2010.

For more information visit http://tsxventure.com/

Neovasc was recognized as a TSX Venture 50® company in 2011. TSX Venture 50 is a trade-mark of TSX Inc. and is used under license.

About Neovasc Inc.
Neovasc Inc. is a specialty vascular device company that develops, manufactures and markets medical devices for the rapidly growing vascular and surgical marketplace. The company's current products include the Neovasc Reducer™, a novel product in development to treat refractory angina, as well as a line of advanced biological tissue technologies that are used to enhance surgical outcomes and as key components in a variety of third-party medical products. For more information, visit: www.neovasc.com .

Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continues," "estimates," "expects,"and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; history of losses and lack of and uncertainty of revenues, ability to obtain required financing, receipt of regulatory approval of product candidates, ability to properly integrate newly acquired businesses, technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with Canadian securities regulators. Although the Company believes that expectations conveyed by the forward-looking statements are reasonable based on the information available to it on the date such statements were made, no assurances can be given as to the future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements except as otherwise required by applicable law.

SOURCE Neovasc Inc.

For further information:

Corporate contact:            U.S. media & investor contact:
Neovasc Inc.           GendeLLindheim BioCom Partners
Chris Clark           Barbara Lindheim
604 248-4138           212 918-4650


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.